GenSight Biologics Reports Its Cash Position as of March 31, 2017
26 April 2017 - 7:30AM
Business Wire
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN:
FR0013183985, PEA-PME eligible), a biopharma company that discovers
and develops innovative gene therapies for neurodegenerative
retinal diseases and diseases of the central nervous system,
today reported its cash position as of March 31, 2017.
Cash and cash equivalents
GenSight Biologics’ cash and cash equivalents amounted to €48.8
million as of March 31, 2017, compared to €54.0 million as of
December 31, 2016.
Number of outstanding shares
As of March 31, 2017, GenSight Biologics’ number of outstanding
shares was 19,540,453 ordinary shares.
GenSight Biologics will report its financial statements and
update for the first half of 2017 on July 28, 2017.
About GenSight Biologics
GenSight Biologics S.A. is a clinical-stage biotechnology
company discovering and developing novel therapies for
neurodegenerative retinal diseases and diseases of the central
nervous system. GenSight Biologics’ pipeline leverages two core
technology platforms, the Mitochondrial Targeting Sequence (MTS)
and optogenetics for retinitis pigmentosa, to help preserve or
restore vision in patients suffering from severe degenerative
retinal diseases. GenSight Biologics’ lead product candidate,
GS010, is in Phase III trials in Leber’s Hereditary Optic
Neuropathy (LHON), a rare mitochondrial disease that leads to
irreversible low vision and legal blindness in teens and young
adults. Using its gene therapy-based approach, GenSight Biologics’
product candidates are designed to be administered in a single
treatment to each eye by intravitreal injection to offer patients a
sustainable functional visual recovery.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170425006821/en/
GenSight BiologicsThomas Gidoin, +33 (0)1 76 21 72
20Chief Financial
Officertgidoin@gensight-biologics.comorRooneyPartnersMedia
RelationsMarion Janic, +1-212-223-4017mjanic@rooneyco.comorThe
Trout GroupInvestor RelationsChad Rubin,
+1-646-378-2947crubin@troutgroup.com
GenSight Biologics (EU:SIGHT)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
GenSight Biologics (EU:SIGHT)
Historical Stock Chart
Von Apr 2023 bis Apr 2024
